Interview with Aristides Torres Velasco, CEO, Vanquish Mexico
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
Address: Blvd, Adolfo Ruiz Cortines No. 4249, Piso 2 Col. Jardines de la Montana C.P. 14210, Mexico
Tel: 01 800 6334 4505
Web: http://www.vanquish.com.mx/
Laboratorios Vanquish was started in 2003 and as a young company has successfully patented one active molecule for Mexico, the United States, and Europe, while also manufacturing and developing generics in the fields of CNS, cardiovascular, oncology and gynaecology. With a strong portfolio in both the public and private market in Mexico, Vanquish is moving forward and now exporting selected products to the United States, and also has manufacturing operations with a partner company in Brazil.
CNS, cardiovascular, oncology, gynaecology, and dietary supplements
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
Francisco González, CEO of ProMéxico, the Mexican investment agency, describes the strengths of Mexico’s research and industrial base, untapped business opportunities in the pharmaceutical and healthcare sectors, and new export…
Javier Amtmann, the new president of AMIIF, the Mexican association of pharmaceutical innovators, reveals AMIIF’s strategic priorities and key areas of focus. As Chairman of the Board of Menarini Mexico,…
Xavier Valdez analyses the dynamics impacting the Mexican pharmaceutical market and explains why IMS Health is transforming itself to strengthen its position as the partner of choice for decision-makers throughout the…
The Mexican pharmaceutical market’s capacity to change dramatically in a short period of time means that both innovators and generics companies must think strategically and “play their cards right” in…
Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater collaboration between Mexican universities and the pharmaceutical industry to bring…
Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de…
For Cristóbal Thompson, Executive Director of AMIIF, health is a formidable measure of productivity and competitiveness that Mexico can no longer overlook if it is to sustain robust economic growth. He…
Tackling both obesity and diabetes is a primary objective of the National Academy of Medicine of Mexico and requires a holistic, multidisciplinary approach, according to Dr. Graue Wiechers, president of…
Senator Salvador Brito, President of the Health Commission at the Mexican Senate, talks about increasing access to quality healthcare services among the most vulnerable groups in Mexican society, improving and…
Servier GM Florent Darchez, reveals how he turned around a Mexico affiliate that was losing market share to achieve and impressive sales growth of 30 percent a year. Darchez also…
In part two of a two-part interview (read part one here), Mikel Arriola of the IMSS discusses the strategic roadmap IMSS will follow under his tenure with regards to innovation…
In part one of a two-part interview (read part two here), Mikel Arriola, the recently appointed general director of IMSS (Mexican Social Security Institute), which provides health-related services to more…
See our Cookie Privacy Policy Here